BioCentury
ARTICLE | Clinical News

sanofi's iniparib misses breast cancer endpoints

January 28, 2011 1:56 AM UTC

sanofi-aventis Group (Euronext:SAN; NYSE:SNY) said iniparib ( BSI-201) plus Gemzar gemcitabine and carboplatin missed the co-primary endpoints of significantly improving overall survival (OS) and progression-free survival (PFS) vs. Gemzar and carboplatin alone in an open-label, U.S. Phase III trial in 519 women with metastatic triple-negative breast cancer. However, sanofi-aventis said a pre-specified analysis of patients treated in the second- and third-line setting with iniparib plus Gemzar and carboplatin displayed an improvement in OS and PFS that was consistent with what was observed in a Phase II trial for the indication. Iniparib is a poly(ADP-ribose) polymerase (PARP) inhibitor. ...